Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Cancer Research

• Publication date

  2015-04-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1078-0432.CCR-14-2148PMID 25878362
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Ras–Membrane Interface: Isoform-Specific Differences in the Catalytic Domain

  2015influential reference
• KRAS as a Therapeutic Target

  2015cited by this paper
• Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD.

  2015influential reference
• Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

  2015cited by this paper
• Metabolic Dependencies in RAS-Driven Cancers

  2015cited by this paper
• RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

  2015cited by this paper
• Small-molecule modulation of Ras signaling.

  2014cited by this paper
• RAS's cloak of invincibility slips at last?

  2014cited by this paper
• Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers

  2014cited by this paper
• Credibility and reproducibility.

  2014cited by this paper
• Dragging ras back in the ring.

  2014cited by this paper
• Direct Ras Inhibitors Identified from a Structurally Rigidified Bicyclic Peptide Library.

  2014cited by this paper
• DRoP: a water analysis program identifies Ras-GTP-specific pathway of communication between membrane-interacting regions and the active site.

  2014cited by this paper
• Targeting molecular addictions in cancer

  2014cited by this paper
• Integrated RAS signaling defined by parallel NMR detection of effectors and regulators.

  2014cited by this paper
• Drugging the undruggable RAS: Mission Possible?

  2014cited by this paper
• Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.

  2014influential reference
• The allosteric switch and conformational states in Ras GTPase affected by small molecules.

  2013cited by this paper
• Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

  2013cited by this paper
• US National Cancer Institute's new Ras project targets an old foe

  2013cited by this paper
• Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras·GTP-effector interaction.

  2013cited by this paper
• Inhibition of Ras-Effector Interaction by Cyclic Peptides.

  2013cited by this paper
• NMR-based functional profiling of RASopathies and oncogenic RAS mutations

  2013cited by this paper
• Bisphenol A binds to Ras proteins and competes with guanine nucleotide exchange: implications for GTPase-selective antagonists.

  2013cited by this paper
• K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

  2013influential reference
• Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function

  2013cited by this paper
• Mutant and wild-type Ras: co-conspirators in cancer.

  2013cited by this paper
• Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.

  2013cited by this paper
• In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras–effector interaction

  2013cited by this paper
• Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.

  2013cited by this paper
• 'Pathway drug cocktail': targeting Ras signaling based on structural pathways.

  2013cited by this paper
• Prospective Development of Small Molecule Targets to Oncogenic Ras Proteins

  2013cited by this paper
• Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins

  2013cited by this paper
• Ras inhibition via direct Ras binding--is there a path forward?

  2012cited by this paper
• A comprehensive survey of Ras mutations in cancer.

  2012cited by this paper
• The role of G-domain orientation and nucleotide state on the Ras isoform-specific membrane interaction

  2012cited by this paper
• Crystal structures of the state 1 conformations of the GTP‐bound H‐Ras protein and its oncogenic G12V and Q61L mutants

  2012cited by this paper
• Shift in the equilibrium between on and off states of the allosteric switch in Ras-GppNHp affected by small molecules and bulk solvent composition.

  2012cited by this paper
• Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

  2012cited by this paper
• Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation.

  2012cited by this paper
• Binding properties and biological characterization of new sugar-derived Ras ligands

  2011cited by this paper
• An Orthosteric Inhibitor of the Ras-Sos Interaction

  2011cited by this paper
• Analysis of binding site hot spots on the surface of Ras GTPase.

  2011influential reference
• Both the C-Terminal Polylysine Region and the Farnesylation of K-RasB Are Important for Its Specific Interaction with Calmodulin

  2011cited by this paper
• Novel Allosteric Sites on Ras for Lead Generation

  2011cited by this paper
• Stabilizing a weak binding state for effectors in the human ras protein by cyclen complexes.

  2010cited by this paper
• Allosteric Modulation of Ras-GTP Is Linked to Signal Transduction through RAF Kinase*

  2010influential reference
• Ras history

  2010cited by this paper
• Ras membrane orientation and nanodomain localization generate isoform diversity

  2010cited by this paper
• Allosteric modulation of Ras positions Q61 for a direct role in catalysis

  2010influential reference
• Conformational States of Human Rat Sarcoma (Ras) Protein Complexed with Its Natural Ligand GTP and Their Role for Effector Interaction and GTP Hydrolysis*

  2010cited by this paper
• The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin.

  2009cited by this paper
• Ras acylation, compartmentalization and signaling nanoclusters (Review)

  2009cited by this paper
• Mechanisms of Ras membrane organization and signaling: Ras on a rocker

  2008cited by this paper
• Global conformational dynamics in ras.

  2008cited by this paper
• A novel switch region regulates H‐ras membrane orientation and signal output

  2008influential reference
• Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGAP interaction

  2008cited by this paper
• Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins.

  2008cited by this paper
• Identification of Essential Interacting Elements in K-Ras/Calmodulin Binding and Its Role in K-Ras Localization*

  2008cited by this paper
• Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II

  2008cited by this paper
• GEFs and GAPs: critical elements in the control of small G proteins.

  2007cited by this paper
• Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

  2007cited by this paper
• Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf.

  2007cited by this paper
• Structure and dynamics of the full-length lipid-modified H-Ras protein in a 1,2-dimyristoylglycero-3-phosphocholine bilayer.

  2007cited by this paper
• NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation.

  2004cited by this paper
• Design and Characterization of a New Class of Inhibitors of Ras Activation

  2004cited by this paper
• Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.

  2004cited by this paper
• New indene-derivatives with anti-proliferative properties.

  2002cited by this paper
• Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells

  2002cited by this paper
• Calmodulin Binds to K-Ras, but Not to H- or N-Ras, and Modulates Its Downstream Signaling

  2001cited by this paper
• Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase g

  2000cited by this paper
• Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma.

  2000cited by this paper
• Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex: involvement of specific residues of the Sec7 domain.

  1999cited by this paper
• Structural View of the RanImportin Interaction at 2.3 Resolution

  1999cited by this paper
• Guanosine triphosphatase stimulation of oncogenic Ras mutants.

  1999cited by this paper
• Structural view of the Ran-Importin beta interaction at 2.3 A resolution.

  1999cited by this paper
• In vitro inhibition of Ras-Raf association by short peptides.

  1998cited by this paper
• Structural basis for the interaction of Ras with RalGDS.

  1998cited by this paper
• Structural basis for the interaction of Ras with RaIGDS

  1998cited by this paper
• Regional polysterism in the GTP-bound form of the human c-Ha-Ras protein.

  1997cited by this paper
• Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras

  1997cited by this paper
• The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants.

  1997cited by this paper
• Conformational transitions in p21ras and in its complexes with the effector protein Raf-RBD and the GTPase activating protein GAP.

  1996cited by this paper
• Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function.

  1996cited by this paper
• Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules.

  1994cited by this paper
• Three-dimensional structures and properties of a transforming and a nontransforming glycine-12 mutant of p21H-ras.

  1994cited by this paper
• Solution structure and dynamics of ras p21.GDP determined by heteronuclear three- and four-dimensional NMR spectroscopy.

  1994cited by this paper
• Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins.

  1992influential reference
• Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction.

  1988influential reference
• Purification of ras GTPase activating protein from bovine brain.

  1988cited by this paper
• Cloning of bovine GAP and its interaction with oncogenic ras p21

  1988cited by this paper

• Insight into structural dynamics involved in activation mechanism of full length KRAS wild type and P-loop mutants

  2024influential citation
• Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg

  2023cites this paper
• Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors

  2023cites this paper
• RAS‐targeted cancer therapy: Advances in drugging specific mutations

  2023cites this paper
• Next batter up! Targeting cancers with KRAS-G12D mutations.

  2023cites this paper
• NMR 1H, 13C, 15N backbone resonance assignments of wild-type human K-Ras and its oncogenic mutants G12D and G12C bound to GTP

  2023cites this paper
• Excited-state observation of active K-Ras reveals differential structural dynamics of wild-type versus oncogenic G12D and G12C mutants

  2023cites this paper
• Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, β-catenin, and FoxP3.

  2023cites this paper
• An expanded classification of active, inactive, and druggable RAS conformations

  2022cites this paper
• KRAS Inhibitor that Simultaneously Inhibits Nucleotide Exchange Activity and Effector Engagement

  2022cites this paper
• Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.

  2022cites this paper
• Functional differences drive the selection of NRAS mutants in melanoma

  2021cites this paper
• Mechanistic insights into the effect of phosphorylation on Ras conformational dynamics and its interactions with cell signaling proteins

  2021cites this paper
• Analysis of RAS gene mutations in cytogenetically normal de novo acute myeloid leukemia patients reveals some novel alterations

  2021cites this paper
• Small molecule inhibitors of RAS proteins with oncogenic mutations

  2020cites this paper
• Water in Ras Superfamily Evolution

  2020cites this paper
• Homogeneous Dual-Parametric-Coupled Assay for Simultaneous Nucleotide Exchange and KRAS/RAF-RBD Interaction Monitoring

  2020cites this paper
• Comparative effects of oncogenic mutations G12C, G12V, G13D, and Q61H on local conformations and dynamics of K-Ras

  2020cites this paper
• Crystal Structure Reveals the Full Ras–Raf Interface and Advances Mechanistic Understanding of Raf Activation

  2020cites this paper
• Prognostic features of NRAS missense mutations in adult acute myeloid leukemia patients

  2020cites this paper
• Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives

  2019cites this paper
• Passenger Hotspot Mutations in Cancer

  2019cites this paper
• Investigation of GTP-dependent dimerization of G12X K-Ras variants using ultraviolet photodissociation mass spectrometry

  2019cites this paper
• Neuroblastoma rat sarcoma mutated melanoma: That’s what we got so far

  2019cites this paper
• Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.

  2019cites this paper
• Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System

  2019cites this paper
• Precision medicine review: rare driver mutations and their biophysical classification

  2019cites this paper
• Targeting Cancer from a Structural Biology Perspective

  2019cites this paper
• Highlights on Specific Biological Targets; Cyclin-Dependent Kinases, Epidermal Growth Factor Receptors, Ras Protein, and Cancer Stem Cells in Anticancer Drug Development

  2019cites this paper
• MeK inhibitors for the treatment of NRAS mutant melanoma

  2018cites this paper
• K-Ras Populates Conformational States Differently from Its Isoform H-Ras and Oncogenic Mutant K-RasG12D.

  2018cites this paper
• MEK inhibitors for the treatment of NRAS mutant melanoma

  2018cites this paper
• Predicting X‐ray solution scattering from flexible macromolecules

  2018cites this paper
• KRAS-Mutant non-small cell lung cancer: From biology to therapy.

  2018cites this paper
• The K-Ras, N-Ras, and H-Ras Isoforms: Unique Conformational Preferences and Implications for Targeting Oncogenic Mutants.

  2018cites this paper
• MeK inhibitors for the treatment of NRAS mutant melanoma

  2018cites this paper
• Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway

  2018cites this paper
• Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy

  2018cites this paper
• Genetic status of KRAS influences Transforming Growth Factor-beta (TGF-β) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis.

  2018cites this paper
• Calmodulin and PI3K Signaling in KRAS Cancers.

  2017cites this paper
• High-Throughput Dual Screening Method for Ras Activities and Inhibitors.

  2017cites this paper
• Mechanistic Insights into the Differential Catalysis by RheB and Its Mutants: Y35A and Y35A-D65A

  2017cites this paper
• Distinct dynamics and interaction patterns in H‐ and K‐Ras oncogenic P‐loop mutants

  2017cites this paper
• Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date

  2017cites this paper
• THE EFFECTS OF ONCOGENIC G 12 D MUTATION ON KRAS STRUCTURE , CONFORMATION AND DYNAMICS

  2017cites this paper
• Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis

  2017cites this paper
• The most oncogenic Ras isoform: specific insights into K-Ras structure, dimerization, and targeting.

  2017cites this paper
• Oncogenic G12D mutation alters local conformations and dynamics of K-Ras

  2017cites this paper
• The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects

  2017cites this paper
• Intrahepatic cholangiocarcinoma: current management and emerging therapies

  2017cites this paper
• Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC

  2017cites this paper
• Structural characterization of NRas Q61L and Q61R mutants and their potential affect on intrinsic hydrolysis

  2016cites this paper
• K-Ras protein as a drug target

  2016cites this paper
• Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.

  2016cites this paper
• The renewed battle against RAS-mutant cancers

  2016cites this paper
• Intrinsic K-Ras dynamics: A novel molecular dynamics data analysis method shows causality between residue pair motions

  2016cites this paper
• Targeting oncogenic signaling proteins : new insights using a FRET-based chemical biology approach

  2016cites this paper
• TCL/RhoJ Plasma Membrane Localization and Nucleotide Exchange Is Coordinately Regulated by Amino Acids within the N Terminus and a Distal Loop Region*

  2016cites this paper
• K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?

  2016cites this paper
• TCL/RhoJ membrane localization and nucleotide exchange

  2016cites this paper
• Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.

  2016cites this paper
• Independent and core pathways in oncogenic KRAS signaling

  2016cites this paper
• Ras Conformational Ensembles, Allostery, and Signaling.

  2016cites this paper
• Mapping the Conformation Space of Wildtype and Mutant H-Ras with a Memetic, Cellular, and Multiscale Evolutionary Algorithm

  2015cites this paper
• KRAS as a Therapeutic Target

  2015cites this paper
• The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?

  2015cites this paper
• Direkte Modulation von Aktivität und Funktion kleiner GTPasen

  2015cites this paper
• Improving Prospects for Targeting RAS.

  2015cites this paper
• RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

  2015influential citation
• Direct Modulation of Small GTPase Activity and Function.

  2015cites this paper
• Ras: structural details to guide direct targeting

  2015cites this paper
• Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

  2015cites this paper
• Can We Harness the Immune System to Target RAS ?

  2015cites this paper
• Metabolic Dependencies in RAS-Driven Cancers

  2015cites this paper
• KRAS mutant lung cancer: progress thus far on an elusive therapeutic target

  2015cites this paper
• pMD-Membrane: A Method for Ligand Binding Site Identification in Membrane-Bound Proteins

  2015cites this paper
• Analyzing the Interaction Between HRAS, STAT3, and LRPPRC in the Mitochondria

  year unknowncites this paper